MS115 TFA 是一种选择性 PRMT5/MEP50 PROTAC 降解剂(DC50 值分别为 17.4 nM 和 11.3 nM),可促进 PRMT5/MEP50 泛素化和降解,并对乳腺癌具有抗癌活性(粉色:PRMT5 和 MEP50 配体 (MS-X40590);蓝色:VHL 配体 (MS-K17554);黑色:连接子)。
产品编号: MS-D23715 CAS No.: 3109377-61-6 分子式: C65H89F4N11O15S 分子量: 1372.53
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

MS115 TFA 是一种选择性 PRMT5/MEP50 PROTAC 降解剂(DC50 值分别为 17.4 nM 和 11.3 nM),可促进 PRMT5/MEP50 泛素化和降解,并对乳腺癌具有抗癌活性(粉色:PRMT5 和 MEP50 配体 (MS-X40590);蓝色:VHL 配体 (MS-K17554);黑色:连接子)。

生物实验数据

生物活性 MS115 TFA is a selective PRMT5/MEP50 PROTAC degrader (DC50 values of 17.4 nM and 11.3 nM, respectively) that promotes PRMT5/MEP50 ubiquitination and degradation and exhibits anticancer activity against breast cancer (pink: PRMT5 and MEP50 ligand (MS-X40590); blue: VHL ligand (MS-K17554); black: linker).
体外研究
(In Vitro)

MS115 (2.1 μM; 120 min) TFA 在无细胞实验中可抑制 PRMT5 甲基转移酶活性,其 IC50 为 2.1 μM。
MS115 (0.01-5 μM; 3-72 h) TFA 可在 MDAMB468 细胞中以浓度和时间依赖的方式强效且选择性地降解 PRMT5 (DC50: 17.4 nM) 和 MEP50 (DC50: 11.3 nM),对两种蛋白的最大降解率均可达 85%以上。
MS115 (0.5-5 μM; 24-72 h, with 1-2 h pretreatment for mechanism assays) TFA 可介导 MDAMB468 细胞中 PRMT5/MEP50 的降解,该过程需要同时结合 PRMT5 与 VHL,并通过泛素-蛋白酶体系统进行。
MS115 (serial dilutions; 7 days) TFA 可抑制 MDAMB468 细胞增殖,其 gIC50 为 5.6 μM。
MS115 (serial dilutions; 5 days) TFA 可抑制 MDAMB453、MDAMB231 和 MCF7 乳腺癌细胞的增殖,其活性与 PRMT5 抑制剂 GSKi 相当。
MS115 (0.004-5 μM; 7 h-3 days) TFA 可在 PC-3 前列腺癌细胞中强效降解 PRMT5/MEP50,其效力优于 PRMT5 降解剂 MS4322。
MS115 (0.5-5 μM; 3 days) TFA 可在 MCF10A 正常乳腺上皮细胞和 PNT2 正常前列腺上皮细胞中降解 PRMT5/MEP50。
MS115 (serial dilutions; 5-6 days) TFA 可在正常上皮细胞系 (MCF10A、PNT2) 中降解 PRMT5/MEP50,且无显著细胞毒性。

Western Blot Analysis

Cell Line: MDAMB468 triple negative breast cancer cells
Concentration: 0.01-0.5 μM (72 h degradation assay); 0.5-5 μM (24 h degradation assay); 2 μM (time-dependent degradation assay)
Incubation Time: 3-48 h (2 μM time-dependent assay); 24 h (0.5-5 μM assay); 72 h (0.01-0.5 μM assay)
Result: Degraded PRMT5 with a DC50 of 17.4 nM and a maximum degradation (Dₘₐₓ) of 86.0 % after 72 h of treatment.
Degraded MEP50 with a DC50 of 11.3 nM and a Dₘₐₓ of 91.4 % after 72 h of treatment.
Induced time-dependent degradation, with PRMT5 degradation detectable by 6 h and MEP50 degradation detectable by 12 h of treatment with 2 μM MS115.
Reduced PRMT5 and MEP50 protein levels to near-undetectable levels at 0.5 μM, and eliminated detectable PRMT5 and MEP50 protein at 5 μM after 24 h of treatment.

Western Blot Analysis

Cell Line: MDAMB468 triple negative breast cancer cells (including sgVHL and sgNTC CRISPR-modified cells)
Concentration: 0.5-5 μM (72 h degradation assay); 5 μM (24 h mechanism assay with 2 h GSKi/VHL-1 pretreatment); 5 μM (24 h mechanism assay with 1 h MG132/MLN4924 pretreatment); 0.5-5 μM (24 h sgVHL/sgNTC cell assay)
Incubation Time: 72 h (0.5-5 μM degradation assay); 24 h (5 μM mechanism assays, with 1-2 h pretreatment); 24 h (0.5-5 μM sgVHL/sgNTC cell assay)
Result: Reduced PRMT5 and MEP50 protein levels to near-undetectable levels and inhibited sDMA levels after 72 h of treatment with 5 μM MS115.
Rescued PRMT5 and MEP50 degradation when cells were pretreated with GSKi or VHL-1, confirming dependence on PRMT5 and VHL binding.
Rescued PRMT5 and MEP50 degradation when cells were pretreated with MG132 or MLN4924, confirming the ubiquitin-proteasome system is required for degradation.

Cell Viability Assay

Cell Line: MDAMB468 triple negative breast cancer cells
Concentration: Serial dilutions
Incubation Time: 7 days
Result: Inhibited MDAMB468 cell proliferation with a growth inhibitory IC50 (gIC50) of 5.6 μM.

Western Blot Analysis

Cell Line: PC-3 prostate cancer cells
Concentration: 0.004-2.5 μM (7 h degradation assay); 0.5-5 μM (3 days degradation and sDMA assay)
Incubation Time: 7 h (0.004-2.5 μM assay); 3 days (0.5-5 μM assay)
Result: Degraded PRMT5 and MEP50 at concentrations lower than MS4322, with detectable degradation at 0.004 μM and near-complete degradation at 2.5 μM after 7 h of treatment.
Reduced PRMT5 and MEP50 protein levels to near-undetectable levels and inhibited sDMA levels after 3 days of treatment with 5 μM MS115.

Western Blot Analysis

Cell Line: MCF10A normal breast epithelial cells, PNT2 normal prostate epithelial cells
Concentration: 0.5-5 μM
Incubation Time: 3 days
Result: Completely degraded PRMT5 and MEP50 after 3 days of treatment with 5 μM MS115, and reduced PRMT5 and MEP50 to near-undetectable levels with 0.5 μM MS115 in MCF10A cells.
Significantly reduced PRMT5 and MEP50 protein levels after 3 days of treatment with 5 μM MS115 in PNT2 cells.

Cell Viability Assay

Cell Line: MCF10A normal breast epithelial cells, PNT2 normal prostate epithelial cells
Concentration: Serial dilutions
Incubation Time: 5 days (MCF10A cells); 6 days (PNT2 cells)
Result: Showed no significant toxicity in MCF10A cells at concentrations up to 15 μM, with cell viability remaining >100% of control at all tested concentrations.
Showed minimal toxicity in PNT2 cells, with cell viability remaining >80% of control even at the highest tested concentration.
体内研究
(In Vivo)

MS115 TFA (50 mg/kg;腹腔注射;单次) 在小鼠中具有良好的动力学特性,单次腹腔注射 50 mg/kg 后可快速吸收并维持持续的血浆暴露水平。

Animal Model: Swiss albino (male)
Dosage: 50 mg/kg
Administration: i.p.; single dose
Result: Achieved a peak plasma concentration (Cmax) of 17.5 μM at 0.5 hours post-administration.
Remained above 200 nM for up to 8 hours post-administration.
性状 固体
颜色 White to off-white

化学信息

分子量 1372.53
分子式 C65H89F4N11O15S
CAS No. 3109377-61-6

储存&溶解度

储存方式

-20°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (72.86 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.7286 mL3.6429 mL7.2858 mL18.2145 mL
5 mM0.1457 mL0.7286 mL1.4572 mL3.6429 mL
10 mM0.0729 mL0.3643 mL0.7286 mL1.8215 mL
15 mM0.0486 mL0.2429 mL0.4857 mL1.2143 mL
20 mM0.0364 mL0.1821 mL0.3643 mL0.9107 mL
25 mM0.0291 mL0.1457 mL0.2914 mL0.7286 mL
30 mM0.0243 mL0.1214 mL0.2429 mL0.6072 mL
40 mM0.0182 mL0.0911 mL0.1821 mL0.4554 mL
50 mM0.0146 mL0.0729 mL0.1457 mL0.3643 mL
60 mM0.0121 mL0.0607 mL0.1214 mL0.3036 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础